Responding to COVID-19 impacts through clinical study and commercialisation in renal dialysis line securement

静脉插管是现代医学中最常用的医疗器械。大多数COVID-19患者将接受静脉插管，以给予药物、液体和抗生素。静脉置管需20分钟HCW时间。然而，高达50%的设备在满足临床需求之前就失效了。接受重症监护的病人常规接受桡动脉插管。这些套管也经常失效，需要更换。如果大多数英国人受到COVID-19的影响，插管失败可能导致数百万人重新插入，不必要的HCW暴露和个人防护装备使用。一家中小企业正在开发一种低成本设备，患者可以佩戴这种设备来保护和固定套管，以降低失败率，改善护理，减少浪费，并最大限度地减少不必要的HCW暴露于COVID-19。由于COVID-19的影响，存在一系列机会来开发用于社区和家庭透析环境的设备，从而提供多种商业化途径。

Intravenous cannulas are the most commonly used patient device in modern medicine. The majority of COVID-19 patients will receive an IV cannula to administer drugs, fluids and antibiotics. IV cannula insertion takes 20 minutes of HCW time. However, up to 50% of devices fail before meeting their clinical need. Patients admitted to intensive care routinely undergo cannulation of the radial artery. These cannulas also frequently fail and need replacing. If the majority of the UK population is affected by COVID-19, cannula failures could lead to millions of reinsertions, unnecessary HCW exposure and PPE use. An SME is developing a low-cost device that is worn by patients to protect and secure cannulas in order to reduce failure rates, improve care, reduce waste and minimise unnecessary HCW exposure to COVID-19.Due to the impacts of COVID-19, a range of opportunities exist to develop the device for application in community and home dialysis settings thereby presenting multiple avenues for commercialisation.